Tag

Glp 1

All articles tagged with #glp 1

health2 days ago•57 min saved

Glp-1 weight-loss jab reverses fatty liver and eases back pain, patient credits 'food-noise' relief

A Daily Mail Health feature follows Karen Holman, who used GLP-1 medications Ozempic and then Mounjaro via telehealth weight-loss program Mosh to combat trauma-driven overeating. She shed about 12 kg in four months, and blood tests showed her fatty liver reversing with liver markers returning to normal. Now weighing roughly 58–60 kg, she reports major relief from lifelong back pain and renewed energy. Medical experts explain GLP-1 meds curb appetite by slowing stomach emptying and altering brain hunger signals, and emphasize better outcomes when combined with structured lifestyle support. The piece also notes ongoing public debate about these medications and the role of behavioral/trauma-informed care in sustainable weight loss.

via Daily Mail|

#fatty-liver #glp-1 #health

business2 days ago•5 min saved

Lilly’s Orforglipron Edges Novo’s GLP-1 Pill in Major Diabetes Trial

In a year-long, head-to-head trial with 1,698 diabetes patients, Eli Lilly’s oral GLP-1 pill orforglipron outperformed Novo Nordisk’s Rybelsus on blood sugar control and weight loss (roughly 15–20 lbs vs 8–11 lbs), with better cardiovascular markers. Higher doses brought more GI side effects (about 10% dropout). The pill can be taken anytime, doesn’t require refrigeration, and Lilly aims for U.S. availability by mid-2026 at about $145–$399 out of pocket.

via Business Insider|

#business #diabetes #glp-1

health3 days ago•42 min saved

GLP-1 Weight-Loss Drugs May Trigger Scurvy if Diet Slips, Experts Warn

Reports of scurvy linked to GLP-1 weight‑loss drugs have risen as these medications curb appetite and food intake, potentially causing vitamin C and other nutrient deficiencies. Experts note that malnutrition risk increases when appetite suppression leads to reduced consumption, and advise nutritional status assessment, meal planning with a dietitian, and targeted supplementation (e.g., vitamin C 100–200 mg) to prevent scurvy and other deficiencies while continuing GLP-1 therapy. Scurvy is reversible with proper supplementation and dietary adjustments.

via Healthline|

#glp-1 #health #malnutrition

business4 days ago•2 min saved

Novo Nordisk slashes Wegovy and Ozempic prices to boost affordability

Novo Nordisk will cut Wegovy by 50% and Ozempic by 35% starting January 2027, setting a $675 per-month price for both drugs and for Rybelsus as well, as it faces competition from Lilly’s Mounjaro/Zepbound and other GLP-1 therapies; the company says the cuts aim to lower out-of-pocket costs for patients with high-deductible plans, and direct-to-patient discounts will remain unchanged.

via CBS News|

#business #glp-1 #novo-nordisk

health5 days ago•1 min saved

Weight-Loss Meds Reframe How People Move, Not Just How They Eat

A profile of Jamie Selzler shows how weight‑loss medications can shift a person’s relationship with activity: once he dreaded workouts as punishment, the meds helped him view exercise as something to be proud of, illustrating how pharmacotherapy can change attitudes toward physical activity beyond just weight loss.

via The New York Times|

#exercise-motivation #glp-1 #health

health7 days ago•6 min saved

GLP-1 obesity drugs and pancreatitis: what the science actually shows

Regulators in the UK and Brazil warned of a possible link between GLP-1 weight‑loss drugs and pancreatitis, but causality remains unclear. With millions using GLP-1 therapies for obesity and related conditions, reported pancreatitis cases and deaths are very rare relative to use (UK: 19 pancreatitis deaths since 2007 and about 1,300 related reports among ~1.6 million users; Brazil: 6 deaths and 145 pancreatitis cases since 2020). Meta-analyses yield mixed results—some show a small risk, others none—while a large real‑world study found no difference in pancreatitis between GLP‑1 users and non‑users with similar risk factors. Ongoing pharmacovigilance and rigorous studies are needed to distinguish true signals from background risk.

via Nature|

#clinical-trials #glp-1 #health

health7 days ago•2 min saved

When GLP-1s Fall Short, Bariatric Surgery Proves Durable for Weight Loss

GLP-1 drugs help some patients lose weight, but they don’t work for everyone. A Maryland woman, Jennie Mixon, chose gastric bypass in 2024 after diabetes and severe obesity; she’s lost about half her weight and has been off insulin since February 2024, regaining energy to enjoy time with her grandkids. Doctors say bariatric surgery remains the most durable weight‑loss option, though only about 1% of eligible patients undergo it, and stigma around the procedure persists as obesity is treated as a disease with complex effects on the body.

via WTOP|

#bariatric-surgery #diabetes #glp-1

health7 days ago•3 min saved

GLP-1 Weight-Loss Drugs Spotlight Rare Nutrient Deficiencies

Australian researchers warn that while GLP-1 weight-loss meds are effective, many clinical trials don’t track diet or nutrient intake, potentially increasing long-term malnutrition risk. Rare cases of deficiencies—such as scurvy (vitamin C) and iron or B‑vitamin shortages—have been reported, but are uncommon. The authors urge closer dietary monitoring in clinical practice and future trials, since deficiency symptoms can mimic GLP-1 side effects. The takeaway: nutrition management is essential for sustained success, not a reason to stop treatment.

via KOMO|

#clinical-trials #diet-monitoring #glp-1

health8 days ago•11 min saved

Old AUD Medications Remain Underused as GLP-1 Buzz Grows

Three FDA-approved meds (naltrexone, acamprosate, disulfiram) can treat alcohol use disorder but are widely underused due to stigma, limited clinician training, and marketing gaps, with only a fraction of diagnosed patients receiving them; meanwhile GLP-1 weight‑loss drugs (like Ozempic) are being studied for reducing drinking, but evidence is not yet conclusive, underscoring the need to treat alcohol use disorder like other chronic diseases by improving access and awareness.

via Business Insider|

#acamprosate #alcohol-use-disorder #disulfiram

life-and-style9 days ago•30 min saved

Weight-loss jabs sharpen a class divide among middle-aged women

New Health Foundation data shows middle-class women aged 30–50 are the dominant private-prescription users of weight‑loss injections like Ozempic and Mounjaro, prompting debate over affordability, ethics, and long-term health effects as researchers highlight side effects and a growing class divide in obesity treatment.

via The Times|

#glp-1 #health-inequality #life-and-style

health10 days ago•6 min saved

Are Weight-Loss Drugs Too Effective? New Trials Spark Safety Questions

Trial results for Eli Lilly’s retatrutide show about 28.7% weight loss after 68 weeks, higher than current meds, but with 12–18% dropout due to side effects and some participants reporting they were losing too much weight. Health experts caution about malnutrition and disordered eating, advocating dosing that is tailored to the patient and kept at the lowest effective level as obesity becomes a chronic disease; Novo Nordisk’s CagriSema uses flexible dosing to manage safety as full data from the retatrutide trial await publication.

via The New York Times|

#cagrisema #glp-1 #health

health11 days ago•3 min saved

GLP-1 Drugs Unlikely to Cause Thyroid Cancer, Review Finds

Researchers at the Clayman Thyroid Center reviewed clinical trials, adverse reports, and real-world data and found little to no evidence that GLP-1 receptor agonists (including Ozempic, Wegovy, and Mounjaro) raise the risk of thyroid cancer, including medullary thyroid cancer. Any uptick in diagnoses is likely due to detection bias from more frequent screening. While large population studies would help solidify certainty, current guidance aligns with avoiding GLP-1s only for people with personal or family histories of medullary thyroid cancer or MEN2.

via Gizmodo|

#detection-bias #glp-1 #health

healthcare11 days ago•2 min saved

Employers test subsidized GLP-1 access through eMed and CVS Caremark

Telehealth company eMed is partnering with CVS Caremark to let employers offer GLP-1 obesity meds to workers via online prescriptions with comprehensive weight-management support; employers can subsidize the drugs to varying degrees, with prices touted as the market’s most cost-effective option. Aon piloted a similar program for its staff, and CVS sees the move as expanding access through its PBM network for up to 30 million Americans. The program combines online cash purchases with secondary coverage to help keep workplace health costs in check, backed by continuous clinical support and monitoring to improve adherence and outcomes.

via Axios|

#employee-benefits #glp-1 #healthcare

explain-it-to-me11 days ago•36 min saved

Weight‑loss drugs that dull the spark: GLP-1 apathy explored

GLP-1 weight‑loss medications are surging in use, with users commonly reporting fatigue and nausea, but clinicians are noting a striking side effect: extreme apathy or a “flat” emotional state that isn’t classic depression. Experts say it may involve dopamine and motivation pathways, making the net impact nuanced and highly dependent on individual circumstances as more people start these therapies.

via vox.com|

#apathy #explain-it-to-me #flat-affect

health14 days ago•3 min saved

Doctors Endorse Weight Watchers as a Practical, Science-Backed Path to Lasting Weight Loss

Doctors are endorsing Weight Watchers as a clinically informed, sustainable weight‑loss program that emphasizes behavior change, nutrition education, and real-life lifestyle shifts. It offers tiered options—Core, Core+ with unlimited coaching, and Med+ with GLP‑1 prescriptions—and has shown greater weight loss and improved glucose control for prediabetes compared with self-directed efforts, while also reducing risks for type 2 diabetes, heart disease, and high blood pressure.

via New York Post|

#behavior-change #diabetes #glp-1